Peptides for arthritis and joint pain: what actually works?
Bottom line: There is no proven injectable “joint-regeneration peptide” that erases osteoarthritis. But peptide-related approaches are not all fiction: semaglutide produced a large pain improvement in a specific group with obesity and knee arthritis, while oral collagen shows a smaller, less certain benefit across several trials.
- Best direct trial
- Semaglutide in 407 adults with obesity and moderate knee osteoarthritis.
- Most accessible option
- Oral collagen supplements, with favorable but inconsistent trial evidence.
- Active knee research
- TPX-100 now has a 270-person Phase 2 knee-osteoarthritis study measuring symptoms and MRI bone shape.
First, identify what is driving the joint pain
“Arthritis” can describe different diseases. Osteoarthritis, rheumatoid arthritis, gout, referred pain, tendon disease, and nerve pain do not have the same cause or treatment. A serious plan starts with the pattern, examination, and appropriate testing—not with a vial chosen from a list.
The strongest peptide-related result
In the STEP 9 randomized trial, people with obesity and knee osteoarthritis received semaglutide or placebo in addition to diet and activity counseling. At 68 weeks, the average WOMAC pain score fell by 41.7 points with semaglutide and 27.5 points with placebo. Weight fell by 13.7% and 3.2%, respectively.
That is a meaningful result, but it applies to a defined population: people with obesity and moderate-to-severe knee-arthritis pain. The study does not show that semaglutide repairs cartilage or treats every painful joint.
Read the full STEP 9 evidence summary.
What about collagen peptides?
An updated meta-analysis combined 11 randomized trials with 870 participants and found improvements in pain and function. Earlier reviewers also warned about heterogeneity and bias. The fair conclusion is “possibly useful for symptoms,” not “rebuilds your knees.”
Read the collagen evidence summary.
See the human evidence behind cartilage-regeneration claims.
The knee-specific peptide to watch: TPX-100
TPX-100 stands apart from most recovery-peptide claims because it already has a randomized paired-knee human program. Earlier results favored the treated knee on function, while a later blinded MRI analysis found less pathological femoral bone-shape change at six and 12 months. A new 270-person study is now testing safety, WOMAC pain and function, KOOS pain frequency, and MRI B-score in mild-to-severe tibiofemoral osteoarthritis.
Read the TPX-100 human data and the result expected in 2027.
What about BPC-157?
BPC-157 has a long animal-research record and strong real-world interest. FDA’s July 2026 review described five small human studies, including a retrospective knee-pain report involving 17 people. A separate 120-person Phase 2 hamstring trial is now recruiting, although it is not a knee-arthritis study.
The FDA advisory committee also recommended BPC-157 for the 503A compounding list in July 2026. That could change pharmacy access, but it is different from approving BPC-157 as a drug for joint pain.
Our verdict: Peptide science may widen the options for joint pain, especially when metabolic health and joint load are part of the problem. BPC-157 is a credible research candidate, but its effect on human arthritis remains an open question.
Primary sources
- STEP 9: semaglutide in people with obesity and knee osteoarthritis (2024; 407 participants)
- Updated meta-analysis of collagen supplementation for knee osteoarthritis (11 trials; 870 participants)
- TPX-100 paired-knee program and blinded MRI bone-shape analysis (2021; 78-person MRI analysis)
- Current 270-person Phase 2 TPX-100 knee study
- FDA briefing document on BPC-157 (July 2026)
- FDA advisory committee meeting and materials (July 23–24, 2026)
- Associated Press report on the advisory committee vote (July 23, 2026)
Last reviewed August 23, 2026. This page compares evidence; it does not select treatment for an individual.